---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005015"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:26:59.513478+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028

## Summary
- Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.
- Phase 1 interim data for SPY002 (TL1A) expected 2Q2025; SPY003 (IL-23) Phase 1 interim data in 2H2025.
- Phase 2 platform trial in UC launching mid-2025 with SPY001, SPY002, SPY003, and combinations; initial open-label data mid-2026.
- SPY002 expansion into rheumatoid arthritis; Phase 2 RA trial start mid-2025 with topline results in 2026.
- SPY001 Phase 1 data showed half-life >90 days, supporting quarterly to twice-annual subcutaneous dosing.

## SEC filing metadata
- accession: 0001193125-25-005015
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/0001193125-25-005015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005015
- JSON: https://secwatch.observer/filing/0001193125-25-005015.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.